Knowledge base
1,274 claims across 14 domains
Every claim is an atomic argument with evidence, traceable to a source. Browse by domain or search semantically.
All 1,274ai alignment 325internet finance 263health 211space development 171entertainment 131grand strategy 101energy 23mechanisms 18collective intelligence 14manufacturing 5robotics 5critical systems 3unknown 3teleological economics 1
Clinical AI deregulation is occurring during active harm accumulation not after evidence of safety as demonstrated by simultaneous FDA enforcement discretion expansion and ECRI top hazard designation in January 2026
The FDA's January 6, 2026 CDS enforcement discretion expansion and ECRI's January 2026 publication of AI chatbots as the #1 health technology hazard occurred in the same 30-day window. This temporal coincidence represents the clearest evidence that deregulation is occurring during active harm accumu
food as medicine interventions produce clinically significant improvements during active delivery but benefits fully revert when structural food environment support is removed
A randomized controlled trial presented at AHA 2025 examined DASH-style grocery delivery plus dietitian support versus cash stipends in food-insecure Black adults in Boston. During the 12-week active intervention, the groceries + dietitian arm showed statistically significant BP improvement and LDL
food insecurity independently predicts 41 percent higher cvd incidence establishing temporality for sdoh cardiovascular pathway
The CARDIA prospective cohort study followed 3,616 US adults without preexisting CVD from 2000 to 2020 (mean baseline age 40.1 years, 56% female, 47% Black). Food insecurity at baseline was associated with HR 1.41 for incident CVD after adjustment for income, education, and employment. This is the f
Medically tailored meals produce -9.67 mmHg systolic BP reductions in food-insecure hypertensive patients — comparable to first-line pharmacotherapy — suggesting dietary intervention at the level of structural food access is a clinical-grade treatment for hypertension
The Kentucky MTM pilot enrolled 75 food-insecure hypertensive adults across urban (UK HealthCare) and rural (Appalachian Regional Healthcare) sites. The medically tailored meals arm (5 meals/week for 12 weeks) produced -9.67 mmHg systolic BP reduction, while the grocery prescription arm ($100/month
Rural food-insecure populations enrolled in food assistance interventions at 81 percent versus 53 percent in urban settings, suggesting rural populations may be more receptive to food-based health interventions due to more severe baseline food access constraints
The Kentucky pilot's two-site design revealed a striking enrollment disparity: Appalachian Regional Healthcare (rural) enrolled 26 of 32 referred patients (81%), while UK HealthCare (urban Lexington) enrolled 49 of 92 referred patients (53%). This 28-percentage-point gap suggests rural food-insecure
SNAP benefit loss causes measurable mortality increases in under-65 populations through food insecurity pathways with peer-reviewed rate estimates of 2.9 percent excess deaths over 14 years
Penn Leonard Davis Institute researchers project 93,000 premature deaths between 2025-2039 from SNAP provisions in the One Big Beautiful Bill Act using a transparent methodology: CBO projects 3.2 million people under 65 will lose SNAP benefits; peer-reviewed research quantifies mortality rates compa
SNAP receipt reduces antihypertensive medication nonadherence by 13.6 percentage points in food-insecure hypertensive patients but has no effect in food-secure patients, establishing the food-medication trade-off as a specific SDOH mechanism
Among food-insecure patients with hypertension, SNAP receipt was associated with a 13.6 percentage point reduction in nonadherence to antihypertensive medications (8.17 pp difference between SNAP recipients vs. non-recipients in the food-insecure group). Critically, SNAP showed NO association with i
five adverse sdoh independently predict hypertension risk food insecurity unemployment poverty low education inadequate insurance
A systematic review published in *Hypertension* (AHA journal) analyzed 10,608 records and identified 57 studies meeting inclusion criteria. The review establishes that multiple SDOH domains independently predict both hypertension prevalence and poor blood pressure control: (1) education — higher edu
generic digital health deployment reproduces existing disparities by disproportionately benefiting higher income users despite nominal technology access equity
This study of racially diverse, lower-income populations found that despite high smart device ownership, utilization of remote patient monitoring (RPM), medical apps, and wearables remained significantly lower than in higher-income populations. Medical app usage was significantly lower among individ
racial disparities in hypertension persist after controlling for income and neighborhood indicating structural racism operates through unmeasured mechanisms
The systematic review finds that Black adults have significantly higher hypertension prevalence compared to White adults even when controlling for both individual poverty status AND neighborhood poverty status. This persistence of racial disparity after accounting for standard SDOH measures (income,
tempo pilot creates medicare digital health pathway while medicaid coverage contracts
The TEMPO pilot represents the first combined FDA enforcement-discretion + CMS reimbursement pathway for digital health devices, explicitly targeting hypertension in the 'early cardio-kidney-metabolic' category. Up to 10 manufacturers per clinical area can deploy uncleared devices to Medicare patien
hypertension related cvd mortality doubled 2000 2023 despite available treatment indicating behavioral sdoh failure
The JACC Data Report analyzing 1999–2023 US cardiovascular disease mortality trends reveals a critical divergence: while ischemic heart disease mortality declined during the statin era, hypertensive disease mortality nearly doubled from approximately 23 per 100,000 in 2000 to 43 per 100,000 in 2019,
only 23 percent of treated us hypertensives achieve blood pressure control demonstrating pharmacological availability is not the binding constraint
The JACC study tracking 1999-2023 NHANES data reveals a striking failure mode in US cardiometabolic disease management. Among patients already receiving treatment for hypertension, only 23.4% (95% CI: 21.5%-25.2%) achieved blood pressure control by 2021-2023 criteria. More dramatically, the proporti
semaglutide cardiovascular benefit is 67 percent independent of weight loss with inflammation as primary mediator
The SELECT trial prespecified analysis (N=17,604, semaglutide 2.4mg weekly vs placebo) found no evidence that semaglutide's MACE reduction was mediated by time-varying weight loss. The benefit was consistent across ALL baseline BMI and waist circumference categories, with no treatment heterogeneity
pcsk9 inhibitors achieved only 1 to 2 5 percent penetration despite proven efficacy demonstrating access mediated pharmacological ceiling
PCSK9 inhibitors (evolocumab, alirocumab) demonstrated 15% MACE reduction in FOURIER (2017) and ODYSSEY OUTCOMES (2018) trials on top of statin therapy—proven individual efficacy with FDA approval and ACC/AHA guideline endorsement. Yet population penetration remained catastrophically low: only 0.9%
enhanced aca premium tax credit expiration creates second simultaneous coverage loss pathway above medicaid income threshold
The expiration of enhanced ACA premium tax credits (APTCs) at the end of 2025 creates a structurally distinct coverage loss mechanism from OBBBA's Medicaid cuts. Enhanced APTCs, enacted in the American Rescue Plan Act (2021) and extended through the Inflation Reduction Act (2022), provided substanti
caregiver workforce crisis shows all 50 states experiencing shortages with 43 states reporting facility closures signaling care infrastructure collapse
The paid caregiving workforce crisis has reached universal geographic scope and is now causing structural capacity loss. All 50 US states report home care worker shortages, 92% of nursing homes report significant or severe workforce shortages, and approximately 70% of assisted living facilities face
family caregiving functions as poverty transmission mechanism forcing debt savings depletion and food insecurity on working age population
Nearly half of family caregivers experience at least one major financial impact from their caregiving responsibilities: taking on debt, stopping retirement savings contributions, or becoming unable to afford food. This represents a systematic transfer of elderly care costs from the formal healthcare
federal budget scoring methodology systematically undervalues preventive interventions because 10 year window excludes long term savings
The CBO vs. ASPE divergence on Medicare GLP-1 coverage reveals a structural bias in how prevention economics are evaluated at the federal policy level. CBO estimates that authorizing Medicare coverage for anti-obesity medications would increase federal spending by $35 billion over 2026-2034. ASPE's
glp 1 multi organ protection creates compounding value across kidney cardiovascular and metabolic endpoints
The FLOW trial was designed as a kidney outcomes study but revealed benefits across multiple organ systems in the same patient population. In 3,533 patients with type 2 diabetes and chronic kidney disease:
glp 1 persistence drops to 15 percent at two years for non diabetic obesity patients undermining chronic use economics
Real-world claims data from 125,474 commercially insured patients initiating GLP-1 receptor agonists for obesity (without type 2 diabetes) reveals a persistence curve that fundamentally challenges the economic model: 46.3% remain on treatment at 180 days, 32.3% at one year, and approximately 15% at
home based care could capture 265 billion in medicare spending by 2025 through hospital at home remote monitoring and post acute shift
Up to $265 billion in care services—representing 25% of total Medicare cost of care—could shift from facilities to home by 2025, a 3-4x increase from current baseline (~$65 billion). This migration is enabled by three converging forces: proven cost savings from hospital-at-home models (19-30% saving
japan demographic trajectory provides 20 year preview of us long term care challenge
Japan is the most aged country in the world with 28.4% of its population aged 65+ as of 2019, expected to plateau at approximately 40% in 2040-2050. The country currently has 6 million people aged 85+, projected to reach 10 million by 2040. This represents the demographic reality the United States w
japan ltci proves mandatory universal long term care insurance is viable at national scale
Japan implemented mandatory public Long-Term Care Insurance (LTCI) on April 1, 2000, creating a universal system that has operated continuously for 25 years. The system is financed through 50% mandatory premiums (all citizens 40+) and 50% taxes (split between national, prefecture, and municipal leve
lower income patients show higher glp 1 discontinuation rates suggesting affordability not just clinical factors drive persistence
Among the factors associated with GLP-1 discontinuation in commercially insured populations, income level emerges as a significant predictor: lower-income patients show higher discontinuation rates even when controlling for other factors.
Page 6 of 9